Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2017-12-26 |
Vivus (USA - CA) |
chief executive officer |
|
nomination |
|
Resignation |
2017-12-26 |
HTG Molecular Diagnostics (USA - AZ) Merck KGaA (Germany) |
companion diagnostic |
|
development |
Cancer - Oncology |
Collaboration agreement |
2017-12-26 |
Peregrine Pharmaceuticals (USA - CA) |
presdient - chief executive officer |
|
nomination |
Cancer - Oncology |
Nomination |
2017-12-22 |
Roche (Switzerland) Accenture (Ireland) |
digital data integration services |
|
services contract |
Technology - Services - Cancer - Oncology |
Services contract |
2017-12-22 |
Formycon (Germany) Aristo Pharma (Germany) FYB202 GmbH & Co (Germany) |
FYB202 - biosimilar version of ustekinumab - biosimilar ustekinumab |
|
joint-venture |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases - Digestive diseases |
Joint-venture agreement |
2017-12-22 |
Antisense Therapeutics (Australia) myTomorrows (The Netherlands) |
ATL1103 - atesidorsen |
acromegaly |
collaboration |
Rare diseases - Hormonal diseases - Endocrine diseases |
Collaboration agreement |
2017-12-21 |
immatics biotechnologies (Germany) Roche (Switzerland) |
tumour-associated peptide (TUMAP)-based cancer vaccine (including IMA942) and other cancer immunotherapies |
gastric cancer, prostate cancer, non-small cell lung cancer |
R&D - research - development - commercialisation |
Cancer - Oncology |
Exercise of an option agreement |
2017-12-21 |
Zealand Pharma (Denmark) Beta Bionics (USA - MA) |
dual hormonal artificial, or bionic, pancreas system - dual-hormone bionic pancreas utilizing both dasiglucagon (liquid formulation glucagon analog) and insulin |
diabetes |
development - collaboration |
Metabolic diseases |
Development agreement |
2017-12-21 |
Janssen Biotech, a J&J company (USA - NJ) Legend Biotech USA and Legend Biotech, subsidiaries of Genscript Biotech Corporation (China) |
LCAR-B38M |
multiple myeloma |
licensing - development - production - commercialisation |
Cancer - Oncology |
Licensing agreement |
2017-12-21 |
Theradiag (France) MSD France (France) |
LISA TRACKER® kits for the monitoring of Remicade® |
|
services contract |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases - Digestive diseases |
Services contract |
2017-12-21 |
Crispr Therapeutics (Switzerland - UK) |
chairman of the board of directors |
|
nomination |
Rare diseases - Genetic diseases - Hematological diseases |
Nomination |
2017-12-21 |
LFB (France) |
chief executive officer |
|
nomination |
Rare diseases - Genetic diseases - Hematological diseases |
Nomination |
2017-12-20 |
Bluebird bio (USA - MA) Merck KGaA (Germany) |
viral vectors |
|
manufacturing - production |
|
Production agreement |
2017-12-20 |
TiGenix (Belgium) |
|
|
|
Autoimmune diseases - Inflammatory diseases - Digestive diseases |
Restructuring |
2017-12-20 |
BMS (USA - NY) Taris Biomedical (USA - MA) |
Opdivo® (nivolumab) and TAR-200 (GemRIS™) |
muscle invasive bladder cancer (MIBC) |
clinical research |
Cancer - Oncology |
Clinical research agreement |
2017-12-19 |
Theradiag (France) HOB Biotech Group (China) |
LISA TRACKER® monitoring assays, auto-immunity IVD tests |
|
co-development - distribution |
Diagnostic - Autoimmune diseases - Immunological diseases |
Distribution agreement |
2017-12-19 |
Confo Therapeutics (Belgium) Roche (Switzerland) |
small molecule agonists of an undisclosed G-protein coupled receptor (GPCR) |
|
research - licensing - commercialisation |
Neurological diseases - Developmental diseases |
Research agreement |
2017-12-19 |
Boehringer Ingelheim (Germany) Roche (Switzerland) |
Locked Nucleic Acid (LNA) oligonucleotides |
inflammatory bowel diseases |
research - R&D - development |
Autoimmune diseases - Inflammatory diseases - Digestive diseases |
Research agreement |
2017-12-19 |
Celltrion Healthcare (South Korea) Hikma Pharmaceuticals (UK) |
Truxima® (CT-P10 - biosimilar rituximab - biosimilar version of Mabthera®/Rituxan® ) |
non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis |
licensing |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Cancer - Oncology |
Licensing agreement |
2017-12-19 |
Five Prime Therapeutics (USA - CA) Zai Lab (China) |
FPA144 |
tumors that overexpress FGFR2b, including gastric and gastro-esophageal junction cancer. |
licensing |
Cancer - Oncology |
Licensing agreement |